Absci Corp director Joseph Sirosh received new equity awards. He was granted 10,100 Restricted Stock Units, each representing one share of common stock, and a stock option for 39,800 shares at an exercise price of $7.34 per share.
The RSUs and options each vest in full on the earlier of the first anniversary of the grant date or Absci’s next annual stockholder meeting, as long as he continues serving the company. After the RSU grant, Sirosh directly holds 33,420 common shares, and he now also holds the new option award.
Absci Corporation reported the results of its Annual Meeting of Stockholders held on June 4, 2026. As of the April 7, 2026 record date, 155,447,428 common shares were outstanding and entitled to vote.
Stockholders elected Class II directors Prof Sir Menelas Pangalos, Ph.D. (74,118,258 votes for, 9,332,380 withheld, 29,904,399 broker non-votes) and Daniel Rabinovitsj (69,590,534 votes for, 13,860,104 withheld, 29,904,399 broker non-votes) to serve until the 2029 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 111,058,992 votes for, 2,198,390 against, and 97,655 abstentions. No other matters were submitted to stockholders.
Absci Corp CFO/CBO Zachariah Jonasson reported a Form 4 transaction where 8,319 shares of common stock were withheld by the company at $6.75 per share to cover tax obligations from vesting restricted stock units.
The filing explains this was a tax-withholding disposition, not a discretionary market trade. After this withholding, Jonasson directly owns 491,464 shares of Absci common stock, showing he retains a substantial equity position in the company.
Absci Corp director Menelas N. Pangalos bought additional company stock in the open market. He purchased 37,453 shares of Absci Corp Common Stock at a price of $5.36 per share. After this transaction, he directly owns 232,308 shares, reflecting a larger personal stake aligned with the company’s equity.
Absci Corporation reported a net loss of $29.6 million for the three months ended March 31, 2026, as it continues to invest in its AI‑driven antibody pipeline. Partner program revenue was $0.2 million, down sharply from $1.2 million a year earlier due to milestone timing and program mix.
Research and development expenses rose to $19.3 million, reflecting higher external preclinical and clinical spending on lead candidate ABS-201 and broader platform work. Selling, general and administrative costs edged down to $9.1 million, while depreciation and amortization fell to $2.7 million as certain lab equipment was retired.
Cash, cash equivalents and marketable securities totaled $125.7 million as of March 31, 2026, against an accumulated deficit of $654.4 million. The company raised $8.0 million in net proceeds via its at‑the‑market equity program and continues to expect significant ongoing spending on clinical development and its Integrated Drug Creation platform.
Absci Corporation reported first quarter 2026 financial and operating results and highlighted progress in its ABS-201 prolactin receptor programs. Revenue was $0.2 million for the quarter, down from $1.2 million a year earlier, while net loss widened to $29.6 million from $26.3 million.
Research and development expenses rose to $19.3 million, mainly to advance ABS-201 and other internal programs, while selling, general, and administrative costs eased slightly to $9.1 million. Cash, cash equivalents, and marketable securities totaled $125.7 million as of March 31, 2026, which the company believes will fund operations into the first half of 2028.
Clinically, Absci completed all four single-ascending-dose cohorts and began dosing the first multiple-ascending-dose cohort in its Phase 1/2a HEADLINE trial of ABS-201 for androgenetic alopecia, with preliminary safety, tolerability, and pharmacokinetic data expected in the second quarter of 2026. The company also introduced ABS-202, an anti-PRLR antibody for an undisclosed inflammation and immunology indication, and outlined plans to initiate a Phase 2 study of ABS-201 in endometriosis in the fourth quarter of 2026.
Absci Corporation presents its Annual Report on Form 10-K describing its AI-native Integrated Drug Creation platform and clinical-stage pipeline focused on antibody therapeutics. The company reports an internally developed lead candidate, ABS-201, in a Phase 1/2a HEADLINE trial and outlines pipeline strategy, IP estate, and regulatory pathways.
Absci says it advanced its first two internal programs from AI design to IND in ~two years at ~$15 million per program. ABS-201 targets the prolactin receptor (PRLR) for androgenetic alopecia and endometriosis; interim proof-of-concept data for AGA are expected in 2H 2026, and a Phase 2 endometriosis study is planned for Q4 2026 subject to data and regulatory review. The company discloses $303.8 million aggregate market value of non-affiliate equity as of June 30, 2025 and 153,021,263 shares outstanding as of March 6, 2026.
Absci Corporation has released its 2026 proxy statement, combining a business update with details for a virtual annual meeting on June 4, 2026. The company highlights ABS-201, an AI-designed antibody that moved from discovery to clinic in about two years at roughly $15 million, versus an industry norm of 4–6 years and more than $50 million. A Phase 1/2a trial for androgenetic alopecia is underway, with clinical proof-of-concept data expected in the second half of 2026, and a global Phase 2 trial in endometriosis targeted for initiation in the fourth quarter of 2026. Absci also introduces its Origin-1 AI model to drive internal pipeline programs and selected partnerships. Stockholders will vote on electing two Class II directors and ratifying Ernst & Young LLP as auditor. The board remains majority independent, and non-employee director cash retainers and equity awards increase under a refreshed 2026 compensation policy.
Absci Corporation major holder Redmile Group, LLC filed an amended Schedule 13D reporting a reduced position in the company’s common stock. The Redmile funds now beneficially own 7,607,449 shares, representing 4.9% of Absci’s common stock, based on 153,021,263 shares outstanding as of March 6, 2026.
On April 10, 2026, Redmile sold 645,867 Absci shares in open market transactions at a weighted average price of $2.979 per share, with individual trades ranging from $2.90 to $3.04. As a result, each reporting person ceased to be a 5% beneficial owner as of that date, while retaining shared voting and dispositive power over the remaining shares.
Absci Corporation’s major shareholder Redmile Group, LLC and Jeremy C. Green have updated their ownership disclosure. They report beneficial ownership of 8,253,316 shares of Absci common stock, representing 5.4% of the outstanding shares, based on 153,021,263 shares outstanding as of March 6, 2026.
The filing explains that their percentage ownership decreased primarily because Absci’s total outstanding common stock increased, rather than from significant share sales. Redmile-managed funds hold the shares directly, while Redmile and Green share voting and investment power and each disclaim beneficial ownership beyond their economic interest.